We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Blood Test Can Accurately Detect Alzheimer's Disease

By LabMedica International staff writers
Posted on 01 Nov 2015
A blood test that can accurately detect the presence of Alzheimer's disease is being developed which would give physicians an opportunity to intervene at the earliest, most treatable stage.

As blood vessels in the brain weaken or become brittle with age, they begin to leak, which allows plasma components including brain-reactive autoantibodies into the brain. More...
There, the autoantibodies can bind to neurons and accelerate the accumulation of β-amyloid deposits, a hallmark of Alzheimer's pathology.

Scientists at the Rowan University School of Osteopathic Medicine (Stratford, NJ, USA) have focused focuses on utilizing autoantibodies as blood-based biomarkers to accurately detect the presence of myriad diseases and pinpoint the stage to which a disease has progressed. By detecting Alzheimer's disease long before symptoms emerge, they hope those with disease-related autoantibody biomarkers will be encouraged to make beneficial lifestyle changes that may help to slow development of the disease.

All humans possess thousands of autoantibodies in their blood and these autoantibodies specifically bind to blood-borne cellular debris generated by organs and tissues all over the body. An individual's autoantibody profile is strongly influenced by age, gender and the presence of specific diseases or injuries, and diseases cause characteristic changes in autoantibody profiles that, when detected, can serve as biomarkers that reveal the presence of the disease. The blood test developed by the team has also shown promise in detecting other diseases, including Parkinson's disease, multiple sclerosis, and breast cancer.

The team developed a microarray, a slide dotted with tiny proteins that light up in reaction to certain autoantibodies, to test for very early stages of Alzheimer’s disease. To test the blood for specific autoantibodies, the investigators took a drop of blood and smeared it on a microarray, a 2.54-cm by 7.62-cm slide dotted with 23,500 tiny proteins, about a third of all proteins made in the human body. When scanned with a laser, the proteins light up in reaction to certain autoantibodies. The brighter the color, the more of that autoantibody is present.

Robert Nagele, PhD, the senior author of the study said, “There are significant benefits to early disease detection because we now know that many of the same conditions that lead to vascular disease are also significant risk factors for Alzheimer's. People found to have preclinical disease can take steps to improve their vascular health, including watching their diet, exercising and managing any weight and blood pressure issues to help stave off or slow disease progression.” The study was presented at the Osteopathic Medical Conference & Exposition, held October 17–21, 2015, in Orlando (FL, USA).

Related Links:

Rowan University School of Osteopathic Medicine 



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.